Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.46 |
| ▸ | PPARG | P37231 | 4/20 | 0.46 |
| ▸ | COMT | P21964 | 1/20 | 0.45 |
| ▸ | ELANE | P08246 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2972386 | 0.81 | NPC1 (0.54) | NPC1RAB9ARXFP1MAPTMAPK1 | |
| SCHEMBL2980269 | 0.78 | COMT (0.50) | COMTELANERXFP1MAPTTHRB | |
| SCHEMBL2978448 | 0.75 | MAPT (0.53) | NPC1RAB9ARXFP1MAPTMAPK1 | |
| SCHEMBL2973717 | 0.74 | PPARG (0.46) | PTGDR2PPARGCOMTMAPT | |
| SCHEMBL2973708 | 0.74 | PPARG (0.46) | PTGDR2PPARGCOMTMAPT | |
| SCHEMBL2972609 | 0.74 | PPARG (0.50) | PTGDR2PPARG | |
| SCHEMBL2972616 | 0.74 | PPARG (0.50) | PTGDR2PPARG | |
| SCHEMBL2982065 | 0.71 | MAPT (0.44) | PTGDR2NPC1RAB9ARXFP1MAPT | |
| SCHEMBL2983621 | 0.71 | CNR1 (0.48) | PPARGMAPT | |
| SCHEMBL13078121 | 0.70 | SMN1; SMN2 (0.42) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286144-A1 | HETEROARYL DERIVATIVES | TAKAHASHI YOKO | 2010-11-11 | — | — | US | disclosed |
| US-20100286144-A1 | HETEROARYL DERIVATIVES | TAKAHASHI YOKO | 2010-11-11 | — | — | US | disclosed |
| US-7781479-B2 | Heteroaryl derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| US-7781479-B2 | Heteroaryl derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| US-7781479-B2 | Heteroaryl derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| US-20080167306-A1 | Novel Heteroaryl Derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20080167306-A1 | Novel Heteroaryl Derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20080167306-A1 | Novel Heteroaryl Derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-07-10 | — | — | US | disclosed |
| EP-1837329-A1 | NOVEL HETEROARYL DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2007-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286144-A1 | HETEROARYL DERIVATIVES | GPR119, SLC2A1, SLC2A4 | PTGDR2 1563/4885PPARG 430/4885COMT 1938/4885 |
| US-20080167306-A1 | Novel Heteroaryl Derivative | GPR119, SLC2A4, SLC5A2 | PTGDR2 1708/4885PPARG 498/4885COMT 2096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.